Department of Pharmacy, King Hussein Cancer Center, Amman, Jordan.
Department of Internal Medicine, King Hussein Cancer Center, Amman, Jordan.
J Chemother. 2024 Jul;36(4):291-298. doi: 10.1080/1120009X.2023.2270833. Epub 2023 Oct 20.
This retrospective study aimed to assess the characteristics and predictors of infusion-related reactions (IRRs) to rituximab in patients with B-cell non-Hodgkin lymphoma (B-NHL). The medical records of adult patients with B-NHL who received their first cycle of rituximab from August 2020 to August 2022 were reviewed. IRRs were defined as any signs experienced by patients during rituximab infusion and graded according to the Common Terminology Criteria for Adverse Events. During the study period, 334 patients were included; among them, 100 patients (30%) developed IRRs (mean age 54.7 (SD 13.2) years). Of the reported IRRs, 90% were grade II reactions, and 10% were grade III reactions. The multivariate analysis identified indolent lymphoma [OR 1.90, = 0.025], no hydrocortisone as premedication [OR 3.03, = 0.029], thrombocytopenia [OR 2.55, = 0.009], and absolute lymphocyte count ≥ 2000 lymphocytes/microL [OR 1.74, = 0.045] as independent predictors for IRRs.
这项回顾性研究旨在评估利妥昔单抗输注相关反应（IRR）在 B 细胞非霍奇金淋巴瘤（B-NHL）患者中的特征和预测因素。回顾性分析了 2020 年 8 月至 2022 年 8 月期间接受首次利妥昔单抗治疗的 B-NHL 成年患者的病历。IRR 定义为患者在利妥昔单抗输注期间经历的任何体征，并根据不良事件常用术语标准进行分级。在研究期间，共纳入 334 例患者，其中 100 例（30%）发生 IRR（平均年龄 54.7[SD 13.2]岁）。报告的 IRR 中，90%为 2 级反应，10%为 3 级反应。多因素分析确定惰性淋巴瘤[OR 1.90，=0.025]、无氢化可的松作为预处理[OR 3.03，=0.029]、血小板减少症[OR 2.55，=0.009]和绝对淋巴细胞计数≥2000 个/μL[OR 1.74，=0.045]为 IRR 的独立预测因素。
